Trials / Terminated
TerminatedNCT02826512
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients: the ABC Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- The Netherlands Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with locally recurrent BRCA1-like, HER2-negative breast cancer that cannot be treated with curative intent by local treatment (surgery, radiotherapy +/- hyperthermia) or patients with metastatic BRCA1-like, HER2-negative breast cancer that have received a maximum of one prior line of treatment for incurable disease will be treated with Niraparib until disease progression
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Niraparib | niraparib 300 mg QD continuously |
Timeline
- Start date
- 2018-05-15
- Primary completion
- 2022-07-01
- Completion
- 2022-07-01
- First posted
- 2016-07-11
- Last updated
- 2022-07-18
Locations
3 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02826512. Inclusion in this directory is not an endorsement.